Ovid Therapeutics Inc (OVID)

Mar 11, 2025, 8:00 AM EDT - 23 days ago

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 4 weeks ago

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

Feb 27, 2025, 8:00 AM EST - 5 weeks ago

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 5, 2025, 8:00 AM EST - 2 months ago

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Sep 11, 2024, 8:00 AM EDT - 7 months ago

Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth

Aug 19, 2024, 11:00 AM EDT - 8 months ago

Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 8 months ago

Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 8 months ago

Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 8 months ago

Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 8 months ago

Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 8 months ago

Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:15 AM EDT - 8 months ago

Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 13, 2024, 8:00 AM EDT - 8 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Aug 12, 2024, 11:55 PM EDT - 8 months ago

Ovid Therapeutics Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 8 months ago

Investors Of Ovid Therapeutics Inc Can Participate In Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 8 months ago

Investors Of Ovid Therapeutics Inc Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 8 months ago

Investors Of Ovid Therapeutics Inc Can Join Fraud Investigation With The Schall Law Firm

Aug 6, 2024, 4:00 PM EDT - 8 months ago

Ovid Therapeutics Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 2, 2024, 10:00 AM EDT - 8 months ago

OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Jul 30, 2024, 8:00 AM EDT - 8 months ago

Ovid Therapeutics to Present at Upcoming August Investor Conferences

Jul 23, 2024, 8:00 AM EDT - 9 months ago

Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

Jul 1, 2024, 8:00 AM EDT - 9 months ago

Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations

Jun 17, 2024, 8:58 AM EDT - 10 months ago

What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?

TAK

Jun 17, 2024, 6:55 AM EDT - 10 months ago

Ovid Therapeutics Reports on Takeda's Announcement of Phase 3 Topline Study Results for Soticlestat

May 14, 2024, 8:00 AM EDT - 11 months ago

Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results

May 13, 2024, 7:00 AM EDT - 11 months ago

Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 9, 2024, 10:48 AM EDT - 1 year ago

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 8, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Feb 28, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 1, 2023, 7:30 AM EST - 1 year ago

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

Nov 3, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Oct 18, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026

Oct 10, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

Sep 26, 2023, 7:30 AM EDT - 1 year ago

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

Sep 20, 2023, 7:30 AM EDT - 1 year ago

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

Aug 4, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

Aug 1, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

Jun 28, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

Jun 26, 2023, 8:00 AM EDT - 1 year ago

Ovid Therapeutics Added to Russell 3000® Index

Jun 13, 2023, 2:12 AM EDT - 1 year ago

Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results

May 5, 2023, 7:30 AM EDT - 2 years ago

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

May 1, 2023, 6:00 AM EDT - 2 years ago

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors